Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
51
52
Next >
Better Growth Stock: Novo Nordisk vs. Eli Lilly
November 16, 2023
These companies have been attracting plenty of attention lately.
Via
The Motley Fool
Why Eli Lilly Stock Flopped While the Market Popped Today
November 15, 2023
The company is apparently gearing up to spend at least $1 billion on a production facility in Europe.
Via
The Motley Fool
Ozempic Shortage Crisis - Germany Weighs Export Restrictions on Novo Nordisk's Drug
November 15, 2023
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic,
Via
Benzinga
Good technical signals and a possible breakout for NOVO-NORDISK A/S-SPONS ADR.
November 15, 2023
A technical analysis of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) shows it may be setting up for a breakout.
Via
Chartmill
Novo Nordisk's Ozempic Usage Suspended - Belgium Implements Temporary Ban Amid Medication Shortage
November 14, 2023
Belgium has temporarily banned Novo Nordisk A/S's (NYSE: NVO) Ozempic for weight
Via
Benzinga
Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment
November 14, 2023
Investors will pay a premium for Novo Nordisk's stock as it has a phenomenal drug in its portfolio.
Via
The Motley Fool
Better Growth Stock: Pfizer vs. Novo Nordisk
November 14, 2023
One is growing now, and the other will grow soon.
Via
The Motley Fool
What's Going On With Novo Nordisk Stock Today?
November 13, 2023
On Saturday, Novo Nordisk A/S (NYSE: NVO) releas
Via
Benzinga
Big Players' Recent Trades in NVO Options
November 13, 2023
Via
Benzinga
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
November 14, 2023
A red-hot product or service right now doesn't mean much if demand for it isn't going to last.
Via
The Motley Fool
Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning
November 14, 2023
It's already taking actions to shore up its future position.
Via
The Motley Fool
3 Safe Stocks to Buy for Solid Returns
November 14, 2023
For investors who seek to keep their returns stable during uncertain times, these safe stocks could be beneficial to their portfolios.
Via
InvestorPlace
What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year
November 13, 2023
Pfizer Inc (NYSE: PFE) is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity
Via
Benzinga
Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly
November 13, 2023
Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart...
Via
Benzinga
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
November 13, 2023
Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes.
Via
Investor's Business Daily
The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’
November 13, 2023
Investors curious to identify the next magnificent 7 stock should start here as the clues are fairly straightforward.
Via
InvestorPlace
Better Buy Now: Novo Nordisk vs. Eli Lilly
November 13, 2023
Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now?
Via
The Motley Fool
Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial
November 11, 2023
A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complications.
Via
Benzinga
'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead
November 11, 2023
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors,
Via
Benzinga
Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth
November 11, 2023
These stocks offer the best of both worlds.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
November 10, 2023
Via
Benzinga
3 Stocks to Buy for Retirees Looking to Beat Inflation
November 10, 2023
Retired investors looking to weather the current market with above-average returns should buy these inflation-beating retirement stocks.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
November 10, 2023
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape, May Help Control Addiction
November 10, 2023
Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S.
Via
Benzinga
'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer
November 10, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Broadcom Inc. (NASDAQ: AVGO) is a "buy."
Via
Benzinga
Could Novo Nordisk Stock Help You Retire a Millionaire?
November 10, 2023
The stock is up big this year, but it may surprise you just how massive your gains would need to be to reach $1 million.
Via
The Motley Fool
Novo Nordisk Seeks Obesity, Diabetes 'Bolt-On' Deals As It Beefs Up Capacity To Meet Soaring Demand
November 10, 2023
Novo Nordisk A/S (NYSE: NVO) plans to invest more than DKK 42 billion
Via
Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
7 Biotech Stocks to Buy for Big-Time Gains
November 10, 2023
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Via
InvestorPlace
The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100
November 10, 2023
Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue.
Via
The Motley Fool
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.